Sign In
Buy PHAT
$8.23
-0.220 (-2.60%)
At Close: Aug 05, 2026
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
11:01am, Monday, 09'th Jun 2025
The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Phathom Pharmaceuticals price target raised by $6 at Cantor Fitzgerald, here's why
01:05pm, Friday, 06'th Jun 2025
19 Aug
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petit
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
07:59am, Thursday, 15'th May 2025
FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)
10:35am, Thursday, 08'th May 2025
Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Thursday, 01'st May 2025
FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
12:09pm, Thursday, 01'st May 2025
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Thursday, 01'st May 2025
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.42 per share a year ago.
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 01'st May 2025
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescr
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
07:59am, Monday, 28'th Apr 2025
FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
08:00am, Wednesday, 23'rd Apr 2025
• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical
Frazier Life Sciences Appoints Aditya Kohli to Partner
08:00am, Thursday, 17'th Apr 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner.
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
08:00am, Wednesday, 16'th Apr 2025
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
08:00am, Thursday, 03'rd Apr 2025
FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Tuesday, 01'st Apr 2025
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
